Improved Efficacy by Addition of Protein-bound Polysaccharide K to Adjuvant Chemotherapy for Advanced Gastric Cancer

Anticancer Res. 2016 Aug;36(8):4237-41.

Abstract

Aim: To evaluate the efficacy of protein-bound polysaccharide K (PSK) added to S-1 adjuvant chemotherapy for treatment of advanced gastric cancer.

Patients and methods: We retrospectively examined clinicopathological and recurrence-free survival (RFS) data for 136 patients with stage II or III advanced gastric cancer who underwent S-1 adjuvant chemotherapy with or without PSK.

Results: Among 13 clinicopathological factors, non-T4 stage (odds ratio (OR)=0.61; 95% confidence interval (CI)=0.41-0.89; p<0.01), N0-1 (OR=0.65; 95% CI=0.43-0.95; p=0.03) and number of treatment cycles ≥7 (OR=0.37; 95% CI=0.20-0.67; p<0.01) were significant independent factors for better RFS. The number of treatment cycles of S-1 plus PSK was significantly higher than that of S-1 alone (p<0.01).

Conclusion: S-1 adjuvant chemotherapy combined with PSK may reduce recurrence by prolonging the treatment cycles in patients with advanced non-T4 or N0-1 gastric cancer.

Keywords: Advanced gastric cancer; PSK; S-1; adjuvant chemotherapy.

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Antineoplastic Combined Chemotherapy Protocols / administration & dosage*
  • Chemotherapy, Adjuvant*
  • Disease-Free Survival
  • Drug Combinations
  • Female
  • Fungal Proteins / administration & dosage*
  • Humans
  • Male
  • Middle Aged
  • Neoplasm Staging
  • Oxonic Acid / administration & dosage
  • Polysaccharides / administration & dosage*
  • Postoperative Period
  • Stomach Neoplasms / drug therapy*
  • Stomach Neoplasms / pathology
  • Stomach Neoplasms / surgery
  • Tegafur / administration & dosage

Substances

  • Drug Combinations
  • Fungal Proteins
  • Polysaccharides
  • protein-bound polysaccharide K, Basidiomycetes
  • S 1 (combination)
  • Tegafur
  • Oxonic Acid